FDA approves Lilly's Zepbound for obstructive sleep apnea in adults with obesity, showing positive results.

From Nasdaq: 2024-12-20 20:08:17

The FDA approved Zepbound for treating obstructive sleep apnea in adults with obesity. The drug was found to be five times more effective than a placebo in reducing breathing disruptions. In clinical trials, Zepbound led to 29 fewer breathing disruptions per hour compared to six with placebo in adults using PAP therapy. After one year, 42% of adults on Zepbound experienced remission or mild OSA, compared to 16% on placebo. Side effects may include nausea, diarrhea, and fatigue. Obstructive sleep apnea is a serious condition that can lead to pauses in breathing during sleep. Visit rttnews.com for more health news.



Read more at Nasdaq: FDA Approves Lilly’s Zepbound To Treat Obstructive Sleep Apnea In Adults With Obesity